Related Experiment Video
Updated: May 12, 2026
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Initial therapy of mantle cell lymphoma
Therapeutic Advances in Hematology
|April 5, 2013
Summary
Mantle cell lymphoma, a type of non-Hodgkin lymphoma, presents challenges with high relapse rates. Advances in aggressive and less aggressive therapies are improving outcomes, with median survival now exceeding five years.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Mantle cell lymphoma (MCL) is a distinct subtype of B-cell non-Hodgkin lymphoma.
- It typically affects older males, often presenting at advanced stages with extranodal involvement.
- Historically, MCL had high initial response rates but frequent relapses and limited long-term survival (3-4 years median).
Purpose of the Study:
- To review the current understanding of mantle cell lymphoma, including its classification, clinical presentation, and prognostic factors.
- To evaluate the evolving therapeutic landscape, encompassing both aggressive and less aggressive treatment strategies.
- To discuss the impact of recent therapeutic advancements on patient survival rates.
Main Methods:
- Literature review of studies on mantle cell lymphoma classification, clinical features, and treatment outcomes.
- Analysis of data regarding response rates, progression-free survival, and overall survival for various therapeutic approaches.
- Examination of the role of intensive chemotherapy, autologous stem cell transplant, allogeneic transplant, and novel agents.
Main Results:
- Mantle cell lymphoma prognosis is influenced by proliferative rate and morphology, with aggressive variants having poorer outcomes.
- Intensive therapies, including chemotherapy and autologous stem cell transplant in first remission, show high response rates and promising progression-free survival.
- Less aggressive therapies and newer agents are also demonstrating efficacy, particularly in relapsed disease.
- Overall survival for mantle cell lymphoma is improving, with current median survival now reported as 5 or more years.
Conclusions:
- Therapeutic strategies for mantle cell lymphoma are diversifying, balancing aggressive approaches for younger patients with less intensive options.
- While autologous stem cell transplant remains a key intensive therapy, its benefit on overall survival compared to less aggressive treatments requires further establishment.
- Ongoing research into novel agents and consolidation/maintenance strategies holds promise for further improving outcomes in mantle cell lymphoma.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.